Provided by Tiger Fintech (Singapore) Pte. Ltd.

SINO BIOPHARM

7.440
+0.0700.95%
Volume:52.72M
Turnover:389.67M
Market Cap:139.58B
PE:35.51
High:7.480
Open:7.270
Low:7.240
Close:7.370
52wk High:9.120
52wk Low:2.634
Shares:18.76B
HK Float Shares:18.76B
Volume Ratio:1.68
T/O Rate:0.28%
Dividend:0.09
Dividend Rate:1.22%
EPS(LYR):0.209
ROE:15.40%
ROA:5.07%
PB:3.82
PE(LYR):35.51
PS:4.17

Loading ...

SINO BIOPHARM (01177): LM-350 "CDH17 ADC" Completes First Patient Enrollment in Phase I Clinical Trial in Australia

Stock News
·
Sep 25

Sino Biopharmaceutical Limited Announces First Patient Enrolled in Phase I Clinical Trial of Innovative CDH17 ADC LM-350 in Australia

Reuters
·
Sep 25

Sino Biopharmaceutical Stock Falls 1.7% in Hong Kong

Dow Jones
·
Sep 24

Sino Biopharm Enrolls First Patient in Tumor Drug Trial in China

MT Newswires Live
·
Sep 23

SINO BIOPHARM (01177): LM-2417 "NaPi2b/4-1BB Bispecific Antibody" Completes First Patient Enrollment in China Phase I Clinical Trial

Stock News
·
Sep 23

LaNova Medicines, a Subsidiary of Sino Biopharmaceutical, Advances LM-2417 Clinical Trials in China

Reuters
·
Sep 23

Sino Biopharmaceutical Stock Slides 4.5% in Hong Kong, Outperforms Competitors

Dow Jones
·
Sep 23

Guotai Junan Securities Initiates Coverage on SINO BIOPHARM (01177) with "Buy" Rating, Target Price HK$11.25

Stock News
·
Sep 23

BRIEF-Sino Biopharmaceutical Says IND Application For TQF3250 Accepted By NMPA

Reuters
·
Sep 22

Sino Biopharm's Clinical Trial Application for Diabetes Drug Accepted in China

MT Newswires Live
·
Sep 22

Sino Biopharmaceutical Limited's IND Application for TQF3250 Capsules 'GLP-1 Receptor Agonist' Accepted by NMPA

Reuters
·
Sep 22

SINO BIOPHARM (01177): TQF3250 Capsule "GLP-1 Receptor Agonist" Clinical Trial Application Accepted by NMPA

Stock News
·
Sep 22

Sino Biopharmaceutical Ltd - Ind Application for Tqf3250 Accepted by Nmpa

THOMSON REUTERS
·
Sep 22

Sino Biopharmaceutical Stock Sheds 2.8% in Hong Kong

Dow Jones
·
Sep 17

Daiwa Raises SINO BIOPHARM (01177) Target Price to HK$10, Maintains "BUY" Rating

Stock News
·
Sep 17

Sino Biopharmaceutical Stock Rises 1.0% in Hong Kong

Dow Jones
·
Sep 15

Is Sino Biopharmaceutical Limited's (HKG:1177) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Simply Wall St.
·
Sep 13

BUZZ-Hansoh leads slide in HK-listed biotech shares on report of US curbs

Reuters
·
Sep 11

Chinese Pharma Stocks Fall on Potential U.S. Restrictions on Drugs

Dow Jones
·
Sep 11

Sino Biopharmaceutical Stock Sheds 1.2% in Hong Kong, Outperforms Competitors

Dow Jones
·
Sep 10